title: A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris.
abstract: BACKGROUND
  The addition of calcipotriol ointment to PUVA therapy for psoriasis vulgaris results in a lower total UVA dose and a faster onset of response. The addition of calcipotriol cream to PUVA, however, has not been studied.
  
  
  OBJECTIVE
  To investigate whether combining calcipotriol cream with PUVA therapy has a UVA sparing effect.
  
  
  METHODS
  We performed a randomized, multicentre, vehicle-controlled, double-blind, 12-week comparative study including 120 patients with psoriasis covering 20-50% body surface area. The study consisted of a washout phase followed by a 10-week treatment phase. PUVA therapy three times weekly was added within 1 week after randomization. Efficacy was assessed by the Psoriasis Area and Severity Index (PASI).
  
  
  RESULTS
  At baseline the mean PASI scores were 17.5 and 19.2 in the calcipotriol and vehicle (placebo) groups, respectively. At the end of treatment, the mean PASI scores were 2.65 and 7.03 (p<0.01), respectively. A reduction in PASI score >90% was observed in 69% of the patients in the calcipotriol-treated group and in 36.4% of the patients in the vehicle group (p<0.01).
  
  
  CONCLUSIONS
  Calcipotriol cream plus PUVA clearly reduces the cumulative dose of UVA and improves the response of psoriasis vulgaris to PUVA.
authors.affiliation: Hospital Clínic i Provincial, Barcelona, Spain.
authors.forename: H
authors.initials: H
authors.lastname: Torras
authors.forename: A
authors.initials: A
authors.lastname: Aliaga
authors.forename: J L
authors.initials: JL
authors.lastname: López-Estebaranz
authors.forename: I
authors.initials: I
authors.lastname: Hernández
authors.forename: J
authors.initials: J
authors.lastname: Gardeazabal
authors.forename: E
authors.initials: E
authors.lastname: Quintanilla
authors.forename: J M
authors.initials: JM
authors.lastname: Mascaró
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D002117:Calcitriol / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D003131:Combined Modality Therapy; D003879:Dermatologic Agents / Q000008:administration & dosage*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011701:PUVA Therapy; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D012720:Severity of Illness Index; D013030:Spain; D016896:Treatment Outcome
chemical_list: D003879:Dermatologic Agents; C055085:calcipotriene; D002117:Calcitriol